Summary The effects of transforming growth factor beta 1 (TGF-i1) and sodium butyrate on cell proliferation and the urokinase plasminogen activator (uPA) system were examined in normal human breast epithelial cells (HBECs) and in a breast cancer cell line, MDA-MB-231. In HBECs, TGF-31 inhibited cell proliferation and uPA activity, while it augmented plasminogen activator inhibitor-1 (PAI-1) antigen level. Sodium butyrate inhibited both cell proliferation and uPA activity but did not affect the level of PAI-1. In MDA-MB-231, TGF-31 had no effect on cell proliferation but increased uPA activity and PAI-1 antigen level; sodium butyrate inhibited both cell proliferation and uPA activity but had no effect on PAI-1 level. Moreover, in the presence of plasminogen, cell detachment could be modulated by the level of cell-associated uPA. Our results indicate (1) that the effects of TGF-13l on cell growth can be dissociated from its effects on the uPANPAI system; (2) that, while TGF-,B1 is a potent inhibitor of cell proliferation and uPA activity in normal cells, it may promote invasion and metastasis of tumour cells by increasing uPA activity and PAI-1 levels; and (3) that sodium butyrate offers a potential approach to preventing tumour development by inhibiting both cell proliferation and invasion.
Urokinase plasminogen activator (uPA) is a multi-domain serine protease that is able to convert the inactive proenzyme plasminogen to plasmin. The plasmin activates prometalloproteinases involved in degradation of collagen, laminin, fibronectin and other matrix extracellular components. This protease cascade is believed to be involved in a variety of physiological as well as pathological processes, including wound healing, tissue remodelling and cancer invasion. Recent studies have shown that uPA is highly expressed during tubular morphogenesis and involution of mammary gland (Delannoy-Courdent et al, 1996; Lund et al, 1996) . uPA-specific antibodies attenuate the metastatic capacity of squamous cell carcinoma to the lungs and lymph nodes (Ossowski et al, 1991) . Overexpression of uPA increases the metastatic rates of both melanoma and prostate cancer (Yu et al, 1991; Achbarou et al, 1994) . The enzymatic activity of uPA is regulated by two specific inhibitors, PAI-l and -2 (Andreasen et al, 1990) and by a specific cell-surface receptor (uPA-R) (Blasi, 1993) . uPA-R binds both active uPA and its inactive proenzyme form, pro-uPA, with high affinity. Pro-uPA can be activated to uPA by plasmin while bound to uPA-R, and receptor-bound uPA in turn activates plasminogen. Concomitant binding of plasminogen and pro-uPA to the cell surface accelerates plasminogen activation, making the cell surface the preferential site for the urokinase pathway of plasminogen activation (Ellis et al, 1991) . When uPA complexes with PAI-i on the cell surface, it is internalized and degraded in a process mediated by uPA-R (Blasi, 1993) . Recently, it was reported that tumour-associated uPA and PAI-I are strong and independent negative prognostic factors for breast cancer patients (Bouchet et al, 1994) .
In vitro, uPA and PAls are regulated by a variety of hormones and growth factors. has been shown to be a major regulator of the uPA/PAI-1 system in different cell types, such as keratinocytes, fibroblasts and prostatic and lung carcinoma cells (Laiho et al, 1986; Keski-Oja et al, 1988a and b; Desruisseau et al, 1996) . In keratinocytes and prostate and lung tumour cells, TGF-P1 increases the proteolytic activity of uPA and the synthesis of PAI-1. More recently, it has been reported that in the human breast cancer cell line MDA-MB-23 1, TGF-,B1 increases cell-associated uPA protein and cell-secreted PAI-I levels (Arnoletti et al, 1995) . Another molecule, sodium butyrate, has also been investigated for its anti-tumour activity. Sodium butyrate is a naturally occurring four-carbon fatty acid, which appears to be a potent differentiating agent for a wide range of neoplastic cells in vitro (Prasad, 1980) . In the human colon carcinoma cell line LIM 2405, sodium butyrate stimulates the synthesis of PAI-I but inhibits both uPA and uPA-R, indicating that sodium butyrate alters the balance of uPA/PAI in a manner that favours net decreased plasminogen activator activity (Reeder et al, 1993) .
We have compared the responses to TGF-P1 and sodium butyrate of normal human mammary epithelial cells with the responses of a malignant human mammary epithelial cell line in terms of cell proliferation, of uPA activity and of the level of PAI-1. We have also examined the functional consequences of cellassociated uPA levels by testing for uPA-dependent plasminmediated cell detachment in vitro.
MATERIALS AND METHODS Materials
The plasmin-specific chromogenic substrate H-D-Valyl-L-LeucylLysine-p-nitroanilide dihydrochloride (S-225 1), plasmin-free plasminogen, TGF-,B1 and sodium butyrate were obtained from Sigma (MO, USA). The anti-catalytic antibody against uPA and Imubind Tissue PAI-I ELISA kit were purchased from American Diagnostica (CT, USA). Materials for cell culture were from Eurobio (France), except where otherwise indicated. (Berthon et al, 1992) and cultured in Dulbecco's Modified Eagle Medium (DMEM) F12 (1/1) (Sigma) containing 5% FCS, 10 ,ug ml-' insulin, 5 x 10 M cortisol (Sigma), 100 ng ml-1 cholera toxin (Sigma) and 2 ng ml-' epidermal growth factor (EGF) (Sigma).
[3H]Thymidine incorporation Assays of uPA activity and PAI-1 level Cells were seeded in 35-mm dishes (Greiner Labortechnik, Germany) and 48 h later washed twice with PBS and then treated with TGF-P1 and/or sodium butyrate in serum-free EMEM without phenol red. After 24 h, the culture medium was collected and centrifuged at 13 000 r.p.m. to remove cell debris. The cell monolayers were extracted with 100 mM Tris-HCl pH 7.6/2 mm EDTA/0.4% Triton X-100 (v/v) at 4°C for 15 min and scraped with a rubber policeman. Cell extracts were then centrifuged at 13 000 r.p.m. to remove cell debris. All samples were stored at -20°C until use. In parallel, cells treated in the same condition in different dishes were harvested and counted using a haemocytometer. uPA activity was determined by using the plasminspecific chromogenic substrate S-2251 as described previously (Reinartz et al, 1993) . Briefly, 50 ,ul of mammary cell extracts or culture supematant was incubated with 50 gl of S-2251 (1.5 mM) and 50 gl of plasminogen (60 jig ml-') at 37°C in flat-bottomed microtitre plates. The release of paranitroaniline from S-2251 was determined in each well by measuring the absorbance at 405 nm using a microplate reader (Dynatech MR 700). Controls including buffer alone and extracts with plasminogen were performed in parallel wells. PAI-I levels were measured using an ELISA kit according to the manufacturer's instructions. Effects of TGF-P and sodium butyrate on uPA activity
In HBECs, TGF-,1 decreased cell-associated uPA to about 35% of the control value ( Figure 2A ) and secreted uPA to 10% of the control value ( Figure 2B ). Sodium butyrate reduced the cell-associated ( Figure 2A ) and secreted ( Figure 2B ) uPA activity by about 50%. uPA activity was inhibited to an even greater extent when cells were treated with both sodium butyrate and TGF-1I (about 17% of control for cell-associated uPA and 5% for secreted uPA) ( Cell detachment assay of HBECs. Cells were seeded in 24-well plates and cultured with TGF-B1 and sodium butyrate (NaB) in serum-free medium for 24 h. Cells were then washed and incubated in the absence (A) or presence of 0.4 IU ml-' plasminogen (B) for 1 h at 370C. The plasminogen incubation was also performed in the presence of 100 IU ml-' aprotinin (C) or 10 igg ml-' anti-catalytic uPA antibody (D) for 1 h at 370C. Detached cells were eliminated by washing two times with serum-free medium. Activation of added plasminogen was ensured by rounding and detachment of cells from culture plates. Magnification x200 of cells with aprotinin or neutralizing antibody to uPA in the presence of plasminogen prevented cell detachment ( Figure 6 ).
DISCUSSION
uPA is considered to be an indicator of poor prognosis in breast cancer. Immunocytochemical analysis shows that uPA, PAI-1 and uPA-R are expressed at a higher level in cancerous breast tissues than in benign tissues (Jankun et al, 1993) . However, in our study, we have shown that normal breast epithelial cells (HBECs) possess more uPA activity than the malignant breast cell line MDA-MB-231, whereas the PAI-l levels were similar in both cell types. As mammary epithelial cells possess both uPA and tPA, we have also measured the uPA activity in the presence of amiloride, a specific inhibitor of uPA (Vassali and Belin, 1992) , no conversion of S225 1 was detected in this condition, indicating that the proteolytic activity measured in our conditions is due to the uPA activity (data not shown). One explanation of our observations is that the HBECs have a complete and intact adhesion system, as well as a welldeveloped extracellular matrix. Therefore, these cells might require more proteolytic activity to degrade the matrix for migration in the basal cell culture condition. In contrast, tumoral cells show frequent defects in cell-adhesion receptors, such as the integrins (Gould et al, 1990; Jones et al, 1992) as well as extracellular matrix, including thrombospondin and laminin (Gould et al, 1990; Zabrenetzky et al, 1994) . Consequently, tumour cells might require less proteolytic activity for migration in the basal cell culture condition. Another possibility is that the action of growth factors, such as TGF-P, hepatocyte growth factor (HGF) and fibroblast growth factor (FGF), requires the activation and/or release of these factors from extracellular matrix, which may be degraded by uPA. As normal cells produce more growth factor-binding extracellular Figure 4 matrix molecules, such as heparan sulphate proteoglycans than tumoral cells (Delehedde et al, 1996 ; unpublished results), it is possible that normal cells need more proteolytic activity to degrade the growth factor binding extracellular matrix to maintain cell growth, particularly in serum-free culture conditions. We have shown that in the human breast cancer cell line MDA-MB-231, TGF-,B1 strongly increased cell-associated and secreted uPA activity. When a cell detachment assay was performed, TGF-I1-treated cells became rounded and detached more rapidly than untreated cells. Cell detachment could be prevented by adding a neutralizing antibody against uPA or the serine protease inhibitor aprotinin. These results indicate that TGF-,1 increased uPA activity, which in turn activated plasmin, thus allowing the degradation of extracellular matrix and cell detachment. In addition, we have found that TGF-01 also increased the PAI-I level in the MDA-MB-23 1 cells. These results agree with those of Desruisseau et al (1996) , in which TGF-,1 induced uPA mRNA expression, secreted uPA activity and secreted PAI-1 levels in prostatic cancer cell lines. Additionally, Amoletti et al (1995) have showed that TGF-P1 enhances cell-associated uPA expression and secreted PAI-I levels in the human breast cancer cell line MDA-MB-23, consistent with our results; but the authors did not observe any change in uPA level in conditioned medium, contrary to our findings. However, as the authors measured uPA protein level only, by ELISA, but not uPA activity, it is possible that the protein level of uPA would not correctly reflect its proteolytic activity as it is regulated by other factors, such as PAI-1, PAI-2 and uPA-R (Andreasen et al, 1990; Blassi et al, 1993) . The simultaneous upregulation of uPA and PAI-I in the tumour cells should be considered as being complementary: increased cell-associated uPA induces pericellular protein degradation, favouring cell detachment, while increased PAI-1 levels reduce indiscriminant extracellular matrix degradation, which would deprive invasive cells of the anchorage necessary for cell locomotion. Moreover, Deng et al (1996) have recently reported that PAI-I promotes cell detachment by interacting with vitronectin, independent of its activity to function as a protease inhibitor. In our study, although TGF-,B1 strongly increased uPA and PAI-I in MDA-MB-231 cells, it did not inhibit cell proliferation. This is consistent with the work of Keski-oja et al (1988a and b) , which showed that the human lung carcinoma cell line A549 is not growth inhibited by TGF-, 1, but responds to TGF-,B1 treatment by changes in the expression of matrix components and enhanced proteolytic activity. Additionally, our observations agree with those of Geiser et al (1992) showing that human carcinoma cell lines that are not growth inhibited by TGF-01 are still capable of responding with increased levels of fibronectin, type IV collagenase and PAI-1. The loss of responsiveness of tumour cells to the antiproliferative effect of TGF-P1 appears to be a frequent event in the progression of malignant tumours (Markowitz and Roberts, 1996) . Multiple changes are required for the cells to gain complete resistance to TGF-PI growth inhibition (Fynan and Reiss, 1993) . Recent work has demonstrated that patients suffering from invasive prostatic cancer present a higher plasma TGF-,B level (Ivanovic et al, 1995) , suggesting a role of TGF-1 in tumour invasion. In contrast to MDA-MB-23 1 tumour cells, HBECs were growth inhibited by TGF-01. Moreover, TGF-p1 decreased uPA activity but augmented PAI-I antigen level in these cells. TGF-i1 prevented cell detachment of HBECs by inhibiting uPA activity. These results agree with previous studies in fibroblast cells demonstrating that TGF-i1 reduces expression of proteases, such as collagenase and uPA, while increasing expression of protease inhibitors, such as PAI-I and tissue inhibitor of metalloproteinase (Laiho et al, 1986; Overall et al, 1991) . However, Stampfer et al, (1993) have reported that TGF-P1 strongly induces the mRNA and protein synthesis of uPA and PAI-I in human mammary epithelial cells, but they did not determine the uPA activity. TGF-lI is synthesized as a biologically inactive form, which can be converted into the active form by limited proteolysis. Plasmin is one of the factors capable of activating the latent form of TGF-i1. As TGF-PI is produced by both MDA-MB-231 cells and HBECs (Valverius et al, 1989; Arrick et al, 1990) , the enhanced production of plasmin by TGF-P1 would provide a positive feedback loop in the regulation of plasmin-mediated proteolysis in the breast tumour cell line MDA-MB-23 1, whereas the decreased production of plasmin by TGF-P1 in HBECs would provide a negative feedback in normal breast epithelium.
We have also found that sodium butyrate inhibited both cell proliferation and uPA activity in both HBECs and MDA-MB-231 cells. This is consistent with the finding of Reeder et al (1993) , demonstrating that in the human colon carcinoma cell line LIM 2405, sodium butyrate regulates the balance of uPA/PAI-1 in a manner that favours net decreased plasminogen activator activity. Sodium butyrate has been reported to induce cell differentiation of a wide range of tumour cells (Prasad, 1980) . It thus may prevent tumour development by inhibiting cell proliferation and invasion as well as by inducing cell differentiation.
In conclusion, our results indicate that (1) while TGF-P 1 was a potent inhibitor for cell proliferation and uPA activity in normal cells, it may promote invasion and metastasis of tumour cells by increasing uPA activity and PAI-i levels; (2) sodium butyrate treatment offers a promising approach to preventing tumour development by inhibiting cell proliferation and invasion. However, recent works have demonstrated that uPA, uPA-R and PAI-I influence cell adhesion in a process independent of uPA-mediated proteolysis (Waltz and Chapman, 1994; Deng et al, 1996) . The possibility of such influence on cell adhesion in our model remains unknown and further studies should be performed to understand the mechanism by which TGF-PI and other inhibitory agents regulate cell adhesion/migration in the context of the uPA system. 
